Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-04-01 00:00:00 ET · period of report 2022-03-31 · accession 0001883850-22-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-01 | 2022-03-31 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $399.66 | +1,500 | 30.2K | +5% | +$599.5K |
| DM | 2022-04-01 | 2022-04-01 | REGN | Landry Robert E | EVP Fin CFO | S - Sale+OE | $695.81 | -316 | 28.8K | -1% | -$219.9K |
| D | 2022-04-01 | 2022-03-31 | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $700.99 | -1,184 | 29.1K | -4% | -$830.0K |
| D | 2022-04-01 | 2022-03-31 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -1,500 | 3,500 | -30% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-31 | M | A | 1,500 | $399.66 | 30,244 | D | — | — | |
| 2 | Common | Common Stock | 2022-04-01 | S | D | 15 | $701.98 | 28,744 | D | — | — | |
| 3 | Common | Common Stock | 2022-04-01 | S | D | 301 | $695.50 | 28,759 | D | — | — | |
| 4 | Common | Common Stock | 2022-03-31 | F | D | 1,184 | $700.99 | 29,060 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-03-31 | M | D | 1,500 | $0.00 | 3,500 | D | $399.66 · — to 2024-12-16 | 1,500 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |